To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported.The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.
Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders / Sota, Jurgen; Breda, Luciana; Paroli, Maria Pia; Hashad, Soad; de-la-Torre, Alejandra; Guerriero, Silvana; Tufan, Abdurrahman; Cardona-López, Juanita; José Altamar-García, María; La Bella, Saverio; Vitale, Antonio; Biancalana, Edoardo; DEL GIUDICE, Emanuela; Minoia, Francesca; Al-Mayouf, Sulaiman; Frediani, Bruno; Cantarini, Luca; Fabiani, Claudia. - In: BRITISH JOURNAL OF OPHTHALMOLOGY. - ISSN 1468-2079. - (2025), pp. 1-4. [10.1136/bjo-2025-327410]
Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders
Maria Pia Paroli;Emanuela Del Giudice;Claudia Fabiani
Ultimo
2025
Abstract
To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported.The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.| File | Dimensione | Formato | |
|---|---|---|---|
|
Sota_Tocilizumab effectiveness_2025.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
868.69 kB
Formato
Adobe PDF
|
868.69 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
